Evidence map›Paper›PMID 39356899›Full record

ArticleCritical care science2024

Advancing insights in critical COVID-19: unraveling lymphopenia through propensity score matching - Findings from the Multicenter LYMPH-COVID Study.

José Pedro Cidade, Vicente Cês Souza-Dantas, Rafaela Braga Mamfrim, Renata Carnevale Miranda, Henrique Tommasi Caroli, Natália Almeida Oliveira, Alessandra Figueiredo Thompson, Gabriela E Oliveira, Pedro Póvoa

Abstract readMulticenter Study
In one paragraph

Article in Critical care science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

José Pedro CidadeIntensive Care Unit 4, Department of Intensive Care, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental - Lisbon, Portugal.ORCID http://orcid.org/0000-0002-8359-5171
Vicente Cês Souza-DantasInstituto D'Or de Pesquisa e Ensino - Rio de Janeiro (RJ), Brazil.ORCID http://orcid.org/0000-0002-1865-1704
Rafaela Braga MamfrimHospital Copa D'Or - Rio de Janeiro (RJ), Brazil.
Renata Carnevale MirandaHospital Copa D'Or - Rio de Janeiro (RJ), Brazil.
Henrique Tommasi CaroliHospital Copa D'Or - Rio de Janeiro (RJ), Brazil.
Natália Almeida OliveiraHospital Copa D'Or - Rio de Janeiro (RJ), Brazil.
Alessandra Figueiredo ThompsonHospital Copa D'Or - Rio de Janeiro (RJ), Brazil.ORCID http://orcid.org/0000-0002-9669-9391
Gabriela E OliveiraHospital Copa D'Or - Rio de Janeiro (RJ), Brazil.
Pedro PóvoaIntensive Care Unit 4, Department of Intensive Care, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental - Lisbon, Portugal.ORCID http://orcid.org/0000-0002-7069-7304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo elucidate the impact of lymphopenia on critical COVID-19 patient outcomes.

methodsWe conducted a multicenter prospective cohort study across five hospitals in Portugal and Brazil from 2020 to 2021. The study included adult patients admitted to the intensive care unit with SARS-CoV-2 pneumonia. Patients were categorized into two groups based on their lymphocyte counts within 48 hours of intensive care unit admission: the Lymphopenia Group (lymphocyte serum count < 1 × 109/L) and the Nonlymphopenia Group. Multivariate logistic regression, propensity score matching, Kaplan‒Meier survival curve analysis and Cox proportional hazards regression analysis were used.

resultsA total of 912 patients were enrolled, with 191 (20.9%) in the Nonlymphopenia Group and 721 (79.1%) in the Lymphopenia Group. Lymphopenia patients displayed significantly elevated disease severity indices, including Sequential Organ Failure Assessment and Simplified Acute Physiology Score 3 scores, at intensive care unit admission (p = 0.001 and p < 0.001, respectively). Additionally, they presented heightened requirements for vasopressor support (p = 0.045) and prolonged intensive care unit and in-hospital stays (both p < 0.001). Multivariate logistic regression analysis after propensity score matching revealed a significant contribution of lymphopenia to mortality, with an odds ratio of 1,621 (95%CI: 1,275 - 2,048; p < 0.001). Interaction models revealed an increase of 8% in mortality for each decade of longevity in patients with concomitant lymphopenia. In the subanalysis utilizing three-group stratification, the Severe Lymphopenia Group had the highest mortality rate, not only in direct comparisons but also in Kaplan‒Meier survival analysis (log-rank test p = 0.0048).

conclusionLymphopenia in COVID-19 patients is associated with increased disease severity and an increased risk of mortality, underscoring the need for prompt support for critically ill high-risk patients. These findings offer important insights into improving patient care strategies for COVID-19 patients.

Indexed as

COVID-19Intensive Care UnitsLymphopeniaPropensity ScoreAgedBrazilCritical IllnessFemaleHumansKaplan-Meier EstimateLymphocyte CountMaleMiddle AgedPortugalProspective StudiesSARS-CoV-2

Identifiers

PMID39356899
PMCPMC11463993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.